Feasibility of Different Types of Exercise Training in Perimenopausal Females
POWER
Perimenopause: Window for Exercise and Resilience Pilot Study
1 other identifier
interventional
30
1 country
1
Brief Summary
Throughout the menopause transition, women experience many symptoms (i.e., hot flashes, night sweats) that can significantly reduce their quality of life. Moreover, their risk of heart disease increases substantially. The years before menopause called "perimenopause" present a critical window of intervention to alleviate menopause symptoms and improve health outcomes. Our team is therefore interested in comparing the potential benefits of different approaches including following the Health Canada guidelines (i.e., accumulating 150 min of moderate-to-vigorous aerobic physical activity weekly); performing high-intensity interval training (HIIT), which involves alternating periods of intense exercise with periods of rest; or stretching in perimenopause. As a first step towards this goal, this study will assess how easy and enjoyable the interventions are to follow over a 6-week period. The information gained from this study will be used to perform a larger study with enough participants to assess the health and quality of life impacts of adopting these different strategies in perimenopause.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 12, 2025
CompletedFirst Posted
Study publicly available on registry
August 20, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
September 9, 2025
September 1, 2025
10 months
August 12, 2025
September 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Intervention Adherence
Determined by the percentage of in-person and online sessions attended over those prescribed as well as exercise intensity adherence based on heart rate data collected via Garmin smartwatch
End of week 6
Enrolment
Determined by the percentage of participants enrolled in study over those assessed for eligibility
End of week 6
Study Assessment Adherence
Determined by the percentage of study assessments completed over those included as part of the study.
End of week 6
Attrition
Determined by the percentage of participants who request withdrawal, are lost to follow-up, or experience injury preventing completion of the study over those enrolled
End of week 6
Intervention acceptability
Assessed via an intervention-specific researcher-developed questionnaire
End of week 6
Secondary Outcomes (17)
Systemic insulin resistance
6 weeks
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Calculated as: (fasting insulin*fasting glucose)/22.5 6 weeks
Cardiorespiratory fitness
6 weeks
Body circumferences
6 weeks
Whole-body fat and fat free mass
6 weeks
- +12 more secondary outcomes
Study Arms (3)
Guidelines-based moderate-intensity continuous exercise
EXPERIMENTAL150 weekly minutes of moderate-intensity aerobic activity
High-intensity interval training
EXPERIMENTALPeriods of high intensity effort (1-4 min) interspersed with periods of rest (1-3 min)
Stretching exercise
ACTIVE COMPARATORwhole-body stretching
Interventions
Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity (total intervention is 6 weeks)
Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 75 weekly minutes of high-intensity interval training.
Twice weekly virtual instructor-led whole-body stretching class.
Eligibility Criteria
You may qualify if:
- Biological females in early and late perimenopause. Menopausal stage will be defined according to the Stages of Reproductive Aging Workshop +10 (STRAW+10). According to STRAW+10, perimenopause is characterized by menstrual cycle irregularity, specifically defined as having bleeding in the previous 12 months but at least a 7-day difference from usual menstrual cycle length
- Experiencing menopause symptoms (e.g., hot flashes, night sweats, joint stiffness)
- Aged 40 years or older
- Multiple risk factors for cardiometabolic disease, namely being sedentary (\<30 min of moderate-vigorous physical activity/week), having a BMI ≥25 kg/m2, and a waist circumference indicative of abdominal obesity, specific to BMI (e.g., BMI 25-29.9: WC: 90cm; BMI 30-34.9: WC: 105cm; BMI 35-35.9: WC:115cm).
You may not qualify if:
- History of reproductive surgeries including oophorectomy, hysterectomy, ablation or gender-affirming.
- Diagnosis of cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, cancer (except for non-melanoma skin cancer), respiratory disease (e.g., Chronic Obstructive Pulmonary Disease or severe or uncontrolled asthma), uncontrolled hyper- or hypogonadism (change in medication or dosage in last 6 months and with major symptoms), and/or Polycystic Ovary Syndrome
- Major signs or symptoms (regardless of known diagnosis) of cardiovascular diseases, diabetes, or renal disease
- The use of medication that could impact blood glucose
- Pregnant or post-partum \<12 months, lactating or breast feeding within 3 months of the start of study
- Recreational smoking (e.g., tobacco, smoking)
- Actively engaging in a low-carbohydrate diet (e.g., ketogenic, Atkins)
- Using transdermal hormones, taking exogenous hormones, or receiving exogenous hormones from other means (e.g., intrauterine device)
- Significant weight loss (i.e., \>5 kg) in past 3 months or currently taking weight loss medications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Goldring Centre for High Performance Sport
Toronto, Ontario, M5S 2C9, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- It is not possible to blind participants to their assigned intervention. Care providers are not involved. The outcome assessors for any assessments involving potential for subjectivity in data collection or analysis will be blinded to group assignment.
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 12, 2025
First Posted
August 20, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
September 9, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share